Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Department of Cardiology, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Dis Markers. 2021 Apr 8;2021:8839512. doi: 10.1155/2021/8839512. eCollection 2021.
We conducted a detailed literature search in Medline and Embase databases and collected relevant publications written in English before April 2020. Overall survival (OS) and disease-free survival (DFS) were the primary and secondary outcomes, respectively. Basic features of patients, hazard ratios (HRs), and 95% confidence intervals (CI) were retrieved to assess the correlation between pretreated blood inflammatory markers and patients with bone sarcoma. This meta-analysis used Stata 12.0.
A total of 10 studies containing 1845 cases were included for analysis. Nine of them evaluated the neutrophil lymphocyte ratio (NLR), 7 the platelet lymphocyte ratio (PLR), and 4 the lymphocyte monocyte ratio (LMR). Pooled results revealed that higher pretreatment NLR was associated with poorer OS (HR = 1.76, 95% CI: 1.29-2.41, and < 0.001) and DFS (HR = 1.77, 95% CI: 1.09-2.88, and = 0.021). In contrast, a lower LMR was related to worse OS (HR = 0.73, 95% CI: 0.57-0.92, and = 0.009), but not DFS (HR = 0.68, 95% CI: 0.41-1.11, and > 0.05). Combined results did not show a significant predictive effect of PLR on the clinical outcomes of patients with bone sarcoma (OS : HR = 1.32, 95% CI: 0.99-1.75, and > 0.05; DFS: HR = 1.12, 95% CI: 0.87-1.44, > 0.05).
NLR and LMR might be promising predictive biomarkers for patients with bone sarcoma and could be used to stratify patients and provide personalized therapeutic strategies.
我们在 Medline 和 Embase 数据库中进行了详细的文献检索，并收集了 2020 年 4 月之前发表的英文相关出版物。总生存期（OS）和无病生存期（DFS）分别为主要和次要结局。我们检索了患者的基本特征、风险比（HR）和 95%置信区间（CI），以评估预处理血液炎症标志物与骨肉瘤患者之间的相关性。本荟萃分析使用了 Stata 12.0 软件。
共有 10 项研究包含 1845 例患者被纳入分析。其中 9 项评估了中性粒细胞与淋巴细胞比值（NLR），7 项评估了血小板与淋巴细胞比值（PLR），4 项评估了淋巴细胞与单核细胞比值（LMR）。汇总结果显示，较高的预处理 NLR 与较差的 OS（HR = 1.76，95%CI：1.29-2.41，<0.001）和 DFS（HR = 1.77，95%CI：1.09-2.88，= 0.021）相关。相比之下，较低的 LMR 与较差的 OS（HR = 0.73，95%CI：0.57-0.92，= 0.009）相关，但与 DFS 无关（HR = 0.68，95%CI：0.41-1.11，>0.05）。联合结果表明，PLR 对骨肉瘤患者的临床结局无显著预测作用（OS：HR = 1.32，95%CI：0.99-1.75，>0.05；DFS：HR = 1.12，95%CI：0.87-1.44，>0.05）。
NLR 和 LMR 可能是骨肉瘤患者有前途的预测生物标志物，可用于对患者进行分层并提供个体化的治疗策略。
